Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 Next >
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Launch of CEO Corner Platform
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Provides Update Regarding Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.